Uncategorized

Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future

Published

on

Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version